Colorectal Cancer Clinical Trials

Showing 41-60 of 2,972 trials

How Emotional Granularity Helps Build Resilience in Young and Middle-Aged Colorectal Cancer Survivors

NCT07200388

This study aims to understand how the ability to identify and describe specific emotions (called "emotional granularity") influences coping and adaptation ("resilience") in young and middle-aged colorectal cancer survivors. The main questions to be answer are: 1. How does emotional granularity help build resilience during cancer recovery? 2. How does emotion regulation contribute to resilience building? 3. What specific emotional needs and challenges do survivors experience? This is an observational study where no experimental treatments are provided. Participants will complete an online questionnaire about background, emotions, ways of managing emotions, and ability to cope with stress. A subset of participants will then be invited to take part in a private, 30-60 minute interview to share personal experiences and feelings in more detail.

Colorectal Cancer (CRC)

The Hong Kong Polytechnic University242 participantsStarted Sep 2025

Suzhou, Jiangsu, China • Suzhou, Jiangsu, China • Suzhu, Jiangsu, China

Not Yet RecruitingPhase 2

Combining DCSZ11 With Radiation and Chemotherapy as Neoadjuvant Treatment for pMMR Locally Advanced Rectal Cancer

NCT07580339

The purpose of this study is to evaluate the safety and clinical activity of combining DCSZ11 with radiation and capecitabine/oxaliplatin (CAPOX) for the neoadjuvant treatment of patients with mismatch repair proficient (pMMR) high risk locally advanced rectal cancer.

Rectal Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins30 participantsStarted Jul 2026

Baltimore, Maryland, United States

How Emotional Granularity Helps Build Resilience in Young and Middle-Aged Colorectal Cancer Survivors

Combining DCSZ11 With Radiation and Chemotherapy as Neoadjuvant Treatment for pMMR Locally Advanced Rectal Cancer

Related Searches

Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Adizutecan (ABBV-400) Moves Through the Body of Adult Participants With Unresectable Locally Advanced/Metastatic Colorectal Cancer

Histidine Supplementation for Antitumor Immunity in Colorectal Cancer

GUCY2C Prime-Boost Vaccination for Advanced Colorectal and Small Bowel Adenocarcinomas

No Operation After Short Course Radiotherapy Followed By Consolidation Chemotherapy In Locally Advanced Rectal Cancer

Genomic Services Research Program

A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors

A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6

QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers.

Recurrence Rate After Endoscopic Resection of , Laterally Spreading Tumor Granular Type (LST-G) of the Colon and Rectum: Endoscopic Mucosal Resection vs. Endoscopic Submucosal Dissection

Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer

Addition of Antibiotics to Upfront Treatment Regimen for Colorectal Cancer

Hepatic Arterial Infusion of Liposomal Irinotecan Plus Oxaliplatin and Capecitabine as Adjuvant Therapy for Colorectal Cancer Liver Metastases

Fluorescence Image Guided Surgery Followed by Intraoperative Photodynamic Therapy for Improving Local Tumor Control in Patients With Locally Advanced or Recurrent Colorectal Cancer

Evaluation of Gynecological and Sexual Sequelae

Lifestyle Intervention Among Participants of the French Colorectal Cancer Screening Program (LIFE-SCREEN)

Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer

Randomized Study of Plasma ctDNA Methylation to Guide Adjuvant Chemotherapy Decisions in High-Risk T3N0 Colorectal Cancer

Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)